Verzenio after Ibrance – pro
There is no strong literature support of Verxenio working after failure of Ibrance. erzenio was initially s FDA approved in combination with fulvestrant to treat women with hormone receptor (HR)positive, human epidermal growth factor receptor 2 (HER2)negative advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), whose disease has progressed after hormonal therapy alone to treat adults with HRpositive, HER2negative advanced breast cancer or metastatic breast cancer whose disease has progressed after hormonal therapy and prior chemotherapy.FDA also approved Verzenio (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced or metastatic breast cancer.
The one paper by Wander et al that looked at Verzenio after Ibrance concluded that more study is needed: “demonstrate that a substantial proportion of pts continue to derive clinical benefit with abemaciclib after prior CDK4/6i, highlighting the potential for its use following CDK4/6 blockade. A second subset had early progression, suggesting cross-resistance to CDK4/6i via common pathways. Future effort should be directed towards validating potential biomarkers to guide optimal utilization of continued CDK4/6 blockade in HR+/HER2- MBC.”.
George W. Sledge et al, MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2? Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology 35, no. 25 (September 2017) 2875-2884.
Verzenio, Prescribing Information 2018
Seth Andrew Wander et al,A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). ournal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 1057-1057.